Barclays’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-197,432
| Closed | -$3.72M | – | 7178 |
|
|
2019
Q3 | $3.72M | Buy |
197,432
+70,906
| +56% | +$811K | ﹤0.01% | 2133 |
|
|
2019
Q2 | $1.49M | Buy |
126,526
+109,961
| +664% | +$1.33M | ﹤0.01% | 3259 |
|
|
2019
Q1 | $226K | Sell |
16,565
-70,914
| -81% | -$919K | ﹤0.01% | 4726 |
|
|
2018
Q4 | $896K | Buy |
87,479
+14,251
| +19% | +$182K | ﹤0.01% | 3237 |
|
|
2018
Q3 | $1.22M | Buy |
73,228
+38,753
| +112% | +$700K | ﹤0.01% | 3440 |
|
|
2018
Q2 | $544K | Sell |
34,475
-1,477
| -4% | -$22.4K | ﹤0.01% | 3877 |
|
|
2018
Q1 | $457K | Buy |
35,952
+22,545
| +168% | +$326K | ﹤0.01% | 4067 |
|
|
2017
Q4 | $154K | Sell |
13,407
-135,249
| -91% | -$1.51M | ﹤0.01% | 4908 |
|
|
2017
Q3 | $1.82M | Buy |
148,656
+135,490
| +1,029% | +$1.41M | ﹤0.01% | 2450 |
|
|
2017
Q2 | $150K | Sell |
13,166
-6,477
| -33% | -$120K | ﹤0.01% | 4605 |
|
|
2017
Q1 | $409K | Buy |
19,643
+7,086
| +56% | +$157K | ﹤0.01% | 3607 |
|
|
2016
Q4 | $262K | Buy |
12,557
+9,755
| +348% | +$254K | ﹤0.01% | 3983 |
|
|
2016
Q3 | $92K | Buy |
2,802
+1,992
| +246% | +$60.7K | ﹤0.01% | 4568 |
|
|
2016
Q2 | $20K | Sell |
810
-73,181
| -99% | -$1.98M | ﹤0.01% | 5278 |
|
|
2016
Q1 | $1.78M | Buy |
73,991
+71,519
| +2,893% | +$1.66M | ﹤0.01% | 2025 |
|
|
2015
Q4 | $81K | Sell |
2,472
-9,355
| -79% | -$316K | ﹤0.01% | 4538 |
|
|
2015
Q3 | $379K | Buy |
11,827
+11,418
| +2,792% | +$485K | ﹤0.01% | 3593 |
|
|
2015
Q2 | $22K | Sell |
409
-540
| -57% | -$19.6K | ﹤0.01% | 5634 |
|
|
2015
Q1 | $26K | Buy |
949
+299
| +46% | +$8.21K | ﹤0.01% | 5697 |
|
|
2014
Q4 | $19K | Sell |
650
-900
| -58% | -$16.2K | ﹤0.01% | 6362 |
|
|
2014
Q3 | $18K | Buy |
1,550
+1,374
| +781% | +$20.8K | ﹤0.01% | 6565 |
|
|
2014
Q2 | $4K | Buy |
+176
| New | +$2.48K | ﹤0.01% | 7229 |
|
Barclays's ALDR Position: Q4 2019 in Review
Barclays sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 197,432 shares — an estimated $3.72M sold.
Barclays first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $3.72M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Barclays reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Barclays sold 197,432 Alder Biopharmaceuticals shares in Q4 2019, an estimated $3.72M.
- Barclays first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- Barclays's Alder Biopharmaceuticals position peaked at $3.72M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.